Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1661-1670

  Banerjee, Antara ^a,b   De, Manjarika ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b BANGABASI COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; NITRIC OXIDE; OCTADECYLAMINE; PAROMOMYCIN; PHOSPHATIDYLCHOLINE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNOMODULATION; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE; SPLEEN CELL; TH1 CELL; VISCERAL LEISHMANIASIS;

AMINES; ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNITY, HUMORAL; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; LEISHMANIASIS, VISCERAL; LIPOSOMES; MICE; MICE, INBRED BALB C; PAROMOMYCIN; PHOSPHATIDYLCHOLINES; TRANSFORMING GROWTH FACTOR BETA;

EID: 79952500831     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00524-10     Document Type: Article

References (47)

1. Afrin, F., et al. 2002. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect. Immun. 70:6697-6706.
2. Afrin, F., T. Dey, K. Anam, and N. Ali. 2001. Leishmanicidal activity of stearylamine-bearing liposomes in vitro. J. Parasitol. 87:188-193. (Pubitemid 32172366)
3. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30:2935-2943.
4. Alvar, J., et al. 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:298-319.
5. Antoine, J. C., E. Prina, N. Courret, and T. Lang. 2004. Leishmania spp.: on the interactions they establish with antigen-presenting cells of their mammalian hosts. Adv. Parasitol. 58:1-68.
6. Banerjee, A., J. Roychoudhury, and N. Ali. 2008. Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. J. Antimicrob. Chemother. 61:103-110.
7. Banerjee, A., M. De, and N. Ali. 2008. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J. Immunol. 181:1386-1398.
8. Belkaid, Y., et al. 2002. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168:3992-4000. (Pubitemid 34298404)
9. Berhe, N., et al. 1999. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 13:1921-1925. (Pubitemid 29509552)
10. Carneiro, G., et al. 2010. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J. Liposome Res. 20:16-23.
11. Carvalho, E. M., et al. 1994. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152:5949-5956.
12. Coffman, R. L., D. A. Lebman, and P. Rothman. 1993. Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54:229-270.
13. Croft, S. L., and V. Yardley. 2002. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8:319-342.
14. Dey, T., K. Anam, F. Afrin, and N. Ali. 2000. Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob. Agents Chemother. 44:1739-1742.
15. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407-2412.
16. Fernandes, A. P., et al. 2001. Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice. J. Infect. Dis. 183:1646-1652.
17. Ferreira, L. S., G. A. Ramaldes, E. A. Nunan, and L. A. Ferreira. 2004. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev. Ind. Pharm. 30:289-296.
18. Gaafar, A., et al. 1995. Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections. Clin. Exp. Immunol. 100:239-245.
19. Gamra, M. M., and L. M. el-Hosseiny. 2003. Comparative study of the prophylactic and therapeutic effects of paromomycin, recombinant IL-12 alone or in combination against Cryptosporidium parvum infection in immunosuppressed mice. J. Egypt. Soc. Parasitol. 33:109-122.
20. Gangneux, J. P., A. Sulahian, Y. J. Garin, and F. Derouin. 1997. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum. J. Antimicrob. Chemother. 40:287-289.
21. Gifawesen, C., and J. P. Farrell. 1989. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect. Immun. 57:3091-3096.
22. + T cells. J. Immunol. 165:915-924.
23. Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42:702-707.
24. Jaafari, M. R., et al. 2009. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob. Agents Chemother. 53:2259-2265.
25. Jha, T. K. 2006. Drug unresponsiveness & combination therapy for kalaazar. Indian J. Med. Res. 123:389-398.
26. Klaus, S. N., and D. Kafka. 1992. Topical paromomycin: a safe and effective therapy for cutaneous leishmaniasis, abstr. p. 410-411. Dermatology: progress and perspective. Abstr. Proc. 18th World Congr. Dermatol.
27. Lang, T., P. Ave, M. Huerre, G. Milon, and J. C. Antoine. 2000. Macrophage subsets harbouring Leishmania donovani in spleens of infected BALB/c mice: localization and characterization. Cell. Microbiol. 2:415-430.
28. Liu, D., et al. 2009. The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J. Immunol. 183:1921-1933.
29. Loiseau, P. M., and C. Bories. 2006. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators. Curr. Top. Med. Chem. 6:539-550.
30. Maarouf, M., F. Lawrence, S. Brown, and M. Robert-Gero. 1997. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol. Res. 83:198-202.
31. Maarouf, M., F. Lawrence, S. L. Croft, and M. Robert-Gero. 1995. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res. 81:421-425.
32. Mancassola, R., J. M. Reperant, M. Naciri, and C. Chartier. 1995. Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study. Antimicrob. Agents Chemother. 39:75-78.
33. McMahon-Pratt, D., and J. Alexander. 2004. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol. Rev. 201:206-224. (Pubitemid 39318454)
34. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J. Infect. Dis. 157:973-978.
35. Murray, H. W., J. D. Berman, C. R. Davies, and N. G. Saravia. 2005. Advances in leishmaniasis. Lancet 366:1561-1577.
36. Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection in experimental visceral leishmaniasis. J. Clin. Invest. 83:1253-1257.
37. Nabors, G. S., L. C. Afonso, J. P. Farrell, and P. Scott. 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin-12 and Pentostam. Proc. Natl. Acad. Sci. U. S. A. 92:3142-3146.
38. Pal, S., R. Ravindran, and N. Ali. 2004. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c mice. Antimicrob. Agents Chemother. 48:3591-3593.
39. Papagiannaros, A., C. Bories, C. Demetzos, and P. M. Loiseau. 2005. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother. 59:545-550.
40. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-858.
41. Saha, S., et al. 2006. Immune reponses in kala-azar. Indian J. Med. Res. 123:245-266.
42. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An eight-day method for screening compounds against Leishmania donovani in the golden hamster. J. Protozool. 5:269-273.
43. Sundar, S., and J. Chakravarty. 2008. Paromomycin in the treatment of leishmaniasis. Expert Opin. Investig. Drugs 17:787-794.
44. Sundar, S., and M. Rai. 2005. Treatment of visceral leishmaniasis. Expert. Opin. Pharmacother. 16:2821-2829.
45. Sundar, S., T. K. Jha, C. P. Thakur, P. K. Sinha, and S. K. Bhattacharya. 2007. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356:2571-2581.
46. Sundar, S., V. P. Singh, S. Sharma, M. K. Makharia, and H. W. Murray. 1997. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. 176:1117-1119.
47. Williams, D., A. B. Mullen, and A. J. Baillie. 1998. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J. Pharm. Pharmacol. 50:1351-1356.